Vasorelaxing and receptor binding properties of NZ-105, a novel dihydropyridine derivative, in isolated rabbit aorta
- PMID: 1663336
Vasorelaxing and receptor binding properties of NZ-105, a novel dihydropyridine derivative, in isolated rabbit aorta
Abstract
The vasorelaxing and dihydropyridine receptor binding properties of NZ-105, a new dihydropyridine derivative, were studied using isolated rabbit aorta, and compared with those of nicardipine, nifedipine and diltiazem. NZ-105 (3 x 10(-10)-3 x 10(-9) M), nicardipine (3 x 10(-10), 10(-9) M), and diltiazem (3 x 10(-7), 10(-6) M) selectively relaxed aortic strips precontracted with high-K+ solution (50 mM) with little effect on strips precontracted with phenylephrine (10(-5) M) or clonidine (10(-6) M). The relaxation produced by NZ-105 was of very slow onset, and no recovery was observed after a 2 hr washout with high-K+ or normal bathing solution. NZ-105 (3 x 10(-10)-3 x 10(-9) M) caused a non-parallel depression of the concentration-response curve for the CaCl2-induced contraction in high-K(+)-depolarized rabbit aorta, whereas nicardipine (10(-10), 3 x 10(-10) M), nifedipine (10(-9), 3 x 10(-9) M) and diltiazem (10(-7), 3 x 10(-7) M) all produced a concentration-related rightward displacement of the curve. The depression induced by NZ-105, but not by nicardipine, became greater as the period of preincubation with the drug was prolonged. NZ-105, nicardipine and diltiazem, at the very high concentration of 10(-6) M, caused a slight and noncompetitive inhibition of the concentration-response curves for norepinephrine, prostaglandin F2 alpha, angiotensin II and 5-hydroxytryptamine. NZ-105 displaced 3H-nitrendipine binding to rabbit aortic membranes in a manner similar to that of nicardipine and nifedipine, and this was also incubation time-dependent. These results indicate that NZ-105 possesses selective calcium antagonist properties, with respect to the rabbit isolated vascular smooth muscle, which are of very slow onset and long-lasting. The slow onset of the vasorelaxation may be due to a slow association rate to dihydropyridine receptors. These pharmacological properties of NZ-105 may, at least in part, be responsible for the slow onset and long duration of its antihypertensive action in vivo.
Similar articles
-
Cardiac and vascular effects of NZ-105, a novel dihydropyridine derivative, in vitro.Arch Int Pharmacodyn Ther. 1991 Nov-Dec;314:57-73. Arch Int Pharmacodyn Ther. 1991. PMID: 1668604
-
NZ-105, a new 1,4-dihydropyridine derivative: correlation between dihydropyridine receptor binding and inhibition of calcium uptake in rabbit aorta.Jpn J Pharmacol. 1991 Nov;57(3):337-48. doi: 10.1254/jjp.57.337. Jpn J Pharmacol. 1991. PMID: 1667534
-
Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.Arzneimittelforschung. 1996 Jan;46(1):15-24. Arzneimittelforschung. 1996. PMID: 8821512
-
"Calcium antagonists": a class of drugs with a bright future. Part II. Determination of basic pharmacological properties.Life Sci. 1984 Aug 6;35(6):575-87. doi: 10.1016/0024-3205(84)90252-2. Life Sci. 1984. PMID: 6087068 Review.
-
Animal pharmacology of nicardipine and its clinical relevance.Am J Cardiol. 1987 Jun 30;59(17):3J-8J. doi: 10.1016/0002-9149(87)90206-2. Am J Cardiol. 1987. PMID: 2440294 Review.
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous